Ochsner Precision Cancer Therapies Program to Co-Present Interim Strata Trial Data at Annual Oncology Meeting

The Ochsner Precision Cancer Therapies Program (PCTP) and Strata Oncology, Inc., a precision oncology company, will co-present data from the Strata Trial, a nationwide observational next-generation sequencing screening protocol providing no-cost tumor sequencing and clinical trial matching for 100,000 advanced cancer patients, at the upcoming 2019 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place in Chicago May 31-June 4, 2019.

"The Strata Trial enables routine genomic testing for advanced cancer patients at Ochsner, which has opened an array of options for targeted treatment, as well as enrollment in precision medicine clinical trials available at our cancer center," said Marc Matrana, MD, MSc, FACP, Medical Director of the Ochsner PCTP and Senior Medical Oncologist at the Gayle and Tom Benson Cancer Center.

Dr. Matrana will be presenting “No-Cost Next Generation Sequencing of Advanced Cancer Patients within the Strata Precision Oncology Network Supports Clinical Trial Enrollment,” Saturday, June 1, 8-11 a.m.

"Data from the Strata Trial support the feasibility of using a system-wide genomic testing protocol to identify patients who may be eligible for biomarker-driven trials," said Dan Rhodes, co-founder, chief executive officer, Strata Oncology. "Strata is committed to improving outcomes for patients and accelerating drug approvals through a model that integrates universal genomic sequencing for advanced cancer patients and cutting-edge clinical research."

The Ochsner PCTP offers the region access to the latest in cancer therapeutics, research and advanced diagnostics. It provides an experienced staff including nurses, doctors, researchers, technicians, laboratory personnel, infusion staff, schedulers and a concierge, fully dedicated to early phase trial cancer patients.

“As one of the largest clinical research networks in the Gulf South, patients now have access to a broad portfolio of phase 1 and 2 trials,” said Dr. Matrana. “This allows patients to stay closer to home for these novel therapies. Our physicians collaborate with leading translational scientists at the forefront of modern medicine to review the results of genetic sequencing and other advanced studies to create customized treatment plans based on the most up-to-date research and data.”

For more information about the Ochsner Precision Cancer Therapies Program and to learn more about the Early Phase Trials being conducted at Ochsner, please click here or call 888-995-7405.

###

Ochsner Health System is Louisiana’s largest non-profit, academic, healthcare system. Driven by a mission to Serve, Heal, Lead, Educate and Innovate, coordinated clinical and hospital patient care is provided across the region by Ochsner's 40 owned, managed and affiliated hospitals and specialty hospitals, and more than 100 health centers and urgent care centers. Ochsner is the only Louisiana hospital recognized by U.S. News & World Report as a “Best Hospital” across three specialty categories caring for patients from all 50 states and more than 70 countries worldwide each year. Ochsner employs nearly 25,000 employees and over 4,500 employed and affiliated physicians in over 90 medical specialties and subspecialties and conducts more than 700 clinical research studies. Ochsner Health System is proud to be a tobacco-free environment. For more information, please visit ochsner.org and follow us on Twitter and Facebook.

Are you a member of the Media?

Gain exclusive access to all of our media resources including photos, b-roll video and more.

Register Today